CA2369910A1 - Compositions et procedes pour traiter des maladies hyperproliferatives - Google Patents

Compositions et procedes pour traiter des maladies hyperproliferatives Download PDF

Info

Publication number
CA2369910A1
CA2369910A1 CA002369910A CA2369910A CA2369910A1 CA 2369910 A1 CA2369910 A1 CA 2369910A1 CA 002369910 A CA002369910 A CA 002369910A CA 2369910 A CA2369910 A CA 2369910A CA 2369910 A1 CA2369910 A1 CA 2369910A1
Authority
CA
Canada
Prior art keywords
agonist
rxr
rar
compound
camp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002369910A
Other languages
English (en)
Inventor
Gerard BENOIT
Hinrich Gronemeyer
Michel Lanotte
Marco Gottardis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Strasbourg
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Strasbourg, Bristol Myers Squibb Co filed Critical Centre National de la Recherche Scientifique CNRS
Publication of CA2369910A1 publication Critical patent/CA2369910A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions comportant un agoniste du récepteur X des rétinoïdes et un agent capable d'activer la protéine kinase A. L'invention concerne aussi des procédés pour traiter des maladies hyperprolifératives par l'administration d'un agoniste du récepteur X des rétinoïdes et d'un agent capable d'activer la protéine kinase A.
CA002369910A 1999-04-23 1999-04-23 Compositions et procedes pour traiter des maladies hyperproliferatives Abandoned CA2369910A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/008908 WO2000064260A1 (fr) 1999-04-23 1999-04-23 Compositions et procedes pour traiter des maladies hyperproliferatives

Publications (1)

Publication Number Publication Date
CA2369910A1 true CA2369910A1 (fr) 2000-11-02

Family

ID=22272621

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002369910A Abandoned CA2369910A1 (fr) 1999-04-23 1999-04-23 Compositions et procedes pour traiter des maladies hyperproliferatives

Country Status (5)

Country Link
EP (1) EP1173061A1 (fr)
JP (1) JP2002542268A (fr)
AU (1) AU773928B2 (fr)
CA (1) CA2369910A1 (fr)
WO (1) WO2000064260A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4866201A (en) * 2000-04-13 2001-10-30 Pierre Chambon Compositions and methods for use in modulating immune system function
AU2002229611A1 (en) * 2000-12-08 2002-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
WO2004016196A2 (fr) * 2002-08-14 2004-02-26 Boston Scientific Limited Systemes, procedes et dispositifs relatifs a la pose d'implants medicaux
WO2004026319A2 (fr) * 2002-09-17 2004-04-01 Centre National De La Recherche Scientifique Compositions pharmaceutiques utilisees pour le traitement de cancers
GB0224415D0 (en) * 2002-10-21 2002-11-27 Medical Res Council Compositions
AU2003289467A1 (en) * 2002-12-20 2004-07-14 Eisai Co., Ltd. Pka activity regulator
WO2015109318A2 (fr) 2014-01-17 2015-07-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Méthodes thérapeutiques
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
WO1999063980A1 (fr) * 1998-06-12 1999-12-16 Ligand Pharmaceuticals Inc. Traitement du cancer du sein resistant aux anti-oestrogenes avec des modulateurs de rxr

Also Published As

Publication number Publication date
WO2000064260A1 (fr) 2000-11-02
EP1173061A1 (fr) 2002-01-23
AU4181599A (en) 2000-11-10
JP2002542268A (ja) 2002-12-10
AU773928B2 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
US6653322B1 (en) Therapeutic combinations of RAR antagonists and RXR agonists and use thereof
WO1998008546A9 (fr) Combinaisons therapeutiques d'antagonistes de rar et d'agonistes de rxr
Chomienne et al. Retinoid differentiation therapy in promyelocytic leukemia
AU773928B2 (en) Compositions and methods for treatment of hyperproliferative diseases
Liu et al. Transcriptional activation of the human p21WAF1/CIP1 gene by retinoic acid receptor: correlation with retinoid induction of U937 cell differentiation
CZ206998A3 (cs) Použití retinoidních sloučenin s RAR alfa receptorovou specifickou nebo selektivní aktivitou
US6184256B1 (en) Methods and compositions for use in modulating expression of matrix metalloproteinase genes
US6624154B1 (en) Compositions and methods for treatment of hyperproliferative diseases
US6172112B1 (en) Retinoids and use thereof
CA2223489A1 (fr) Procedes de traitement de cancers a l'aide de 6-¬3-¬1-adamantyl|-4-hydroxyphenyl|
US6713515B2 (en) Retinoic acid receptor antagonists as promoters of angiogenesis
CN106955288B (zh) Fxr激动剂在制备治疗脂肪肉瘤相关疾病药物中的用途
US20020090352A1 (en) Compositions and methods for use in modulating immune system function
Crowe Receptor selective synthetic retinoids as potential cancer chemotherapy agents
US20040122080A1 (en) Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
JP2004528316A (ja) 癌治療のための、レチノイド受容体リガンドおよび選択される細胞毒性剤の相乗的な組み合わせ
MXPA99001757A (en) Therapeutic combinations of rar antagonists and rxr agonists and use thereof
AU2002305072A1 (en) Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
Chomienne et al. Retinoids in acute promyelocytic leukaemia
Chomienne Molecular Basis for Retinoic Acid Effects in Acute Promyelocytic Leukemia

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued